User:Mr. Ibrahem/Mobocertinib

Mobocertinib, sold under the brand name Exkivity, is a medication used to treat non-small cell lung cancer. Specifically it is used for advanced cases with an epidermal growth factor receptor (EGFR) exon 20 insertion mutation. It is taken by mouth once per day.

Common side effects include diarrhea, rash, nausea, inflammation of the mouth, vomiting, decreased appetite, finger nail infections, tiredness, dry skin, and musculoskeletal pain. Other side effects may include kidney problems, low potassium, pancreatitis, pneumonitis, and heart problems such as QTc prolongation. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor that preferentially inhibits epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.

Mobocertinib was approved for medical use in the United States in 2021. While it is available in the United Kingdom, it is not approved in Europe. In the United Kingdom a month of medication costs the NHS about £7800 as of 2022. In the United States this amount costs 24,600 USD.